创新失眠药物莱博雷生正式发往医院及指定药店

Core Insights - Eisai (China) Pharmaceutical Co., Ltd. has announced that its innovative drug, Lemborexant, has arrived in China and completed the drug inspection process, now being distributed to major hospitals and designated pharmacies nationwide, providing a new treatment option for insomnia patients [1][2] - Lemborexant can also be prescribed through the JD Health online platform, addressing the medication needs of insomnia sufferers [1] - The drug works by competitively binding to two orexin receptor subtypes (OX1R and OX2R), precisely regulating the orexin system to induce sleep without suppressing REM sleep, thus improving overall sleep structure [1][2] Product Approval and Market Position - Lemborexant was approved for sale in the United States in 2019 and has since received approval in over 20 countries and regions, including Japan, Canada, Australia, Hong Kong, and Macau [2] - In the U.S., it is indicated for adults with difficulties in falling asleep or maintaining sleep, while in Japan, it is a recommended treatment for insomnia as per the Japanese Consensus on Insomnia Disorder Treatment [2] - The drug received approval from the National Medical Products Administration (NMPA) in China in May 2025 for treating adult insomnia characterized by difficulty in falling asleep and/or maintaining sleep, and is included in the "Guidelines for the Diagnosis and Treatment of Adult Insomnia in China" [2] Strategic Focus - Eisai China positions the neuroscience field, including insomnia, as a key therapeutic area, aiming to provide innovative treatment options and management tools for insomnia patients [2] - The launch of Lemborexant is expected to reshape natural sleep rhythms and redefine sleep health management standards, contributing to the "Healthy China 2030" chronic disease prevention goals [2]